Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist HRS9531 in T2DM patients: A Randomized, Double-blind, Placebo and Open-label Positive-controlled Phase 1b Trial